Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Clinical trial NCT03331198 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03331198
- Sponsor
- Juno Therapeutics, a Subsidiary of Celgene
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-11-27
- Primary completion
- 2027-11-26
- Enrollment
- 320
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.